UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 7, 2021
KIROMIC BIOPHARMA, INC.
(Exact name of registrant as specified in its charter)
Delaware | 001-39619 | 46-4762913 | ||
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer |
7707 Fannin, Suite 140
Houston, TX, 77054
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code (832) 968-4888
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ] | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
[ ] | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
[ ] | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
[ ] | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class | Trading Symbol(s) | Name of Each Exchange on Which Registered | ||
Common Stock, $0.001 par value | KRBP | The Nasdaq Stock Market LLC |
1
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company [X]
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
2
Item 5.02. | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On June 7, 2021, Kiromic BioPharma, Inc. (the “Company”) entered into an Executive Agreement (the “Nunez Agreement”) with Mr. Ignacio Nunez to be its Chief Operating and Manufacturing Officer (“COMO”). The term of the Nunez Agreement commenced on June 7, 2020 and will continue until termination by either the Company or Mr. Nunez. Pursuant to the Nunez Agreement, Mr. Nunez’s base compensation will be $350,000 per year.
The COMO may terminate the Nunez Agreement and COMO’s employment by the Company upon __ days notice. In addition, the Company may also terminate the Nunez Agreement upon __ days notice. If the termination notice by the COMO is other than for “Good Reason” as defined in the Nunez Agreement, the Company shall have no further obligations other than the payment of all compensation and other benefits payable to the COMO through the date of such termination, including any earned but unpaid bonus. Similarly, if the Company terminates the Nunez Agreement “for cause”, upon the death, or permanent disability as defined in the Nunez Employment Agreements, then the Company shall have no further obligations other than the payment of all compensation and other benefits payable to the Executive through the date of such termination, including any earned but unpaid bonus.
The Company will incur further obligations:
● | If the COMO terminates the Nunez Agreement for “Good Reason” as defined in the Executive Employment Agreement, or |
● | If the Company terminates the Nunez Employment Agreement for any reason other than “for cause”, upon the COMO’s death, or disability as defined in the Nunez Agreement. |
Those obligations are outlined below:
1. | the Company shall pay the COMO an amount equal to six (6) months of Executive’s then-current Base Salary (less all applicable tax withholdings) payable in installments during the one year period immediately following the termination date in accordance with the then-current generally applicable payroll schedule of the Company commencing on the first regularly scheduled pay date of the Company processed after Executive has executed, delivered to the Company and not revoked the Release (with the first payment to include a catchup for any amounts that would have been paid had the Release been effective on the termination date); |
2. | the Company shall reimburse of COMO for the first eighteen (18) months of the premiums associated with Executive's continuation of health insurance for him and his family pursuant to COBRA, provided Executive timely elects and is eligible for COBRA benefits; | |
3. | the Company shall pay the Earned But Unpaid Bonus (if any), to be paid at the same time such bonus would have been paid if no such termination had occurred; and | |
4. | the Company shall accelerate all stock options, restricted stock unit and other stock-based awards granted to Executive that were scheduled to vest during the 12 month period immediately following Executive's termination of employment shall become immediately vested and exercisable (if applicable) and with respect to restricted stock units and similar awards. |
Item 8.01Other Events.
On June 7, 2021, the Company issued a press release announcing the appointment of Mr. Ignacio Núñez as Chief Operating and Manufacturing Officer. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
3
Item 9.01 Financial Statements and Exhibit
(d) Exhibits.
The following exhibits are filed with this Current Report on Form 8-K:
4
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
5
Execution
EXECUTIVE EMPLOYMENT AGREEMENT
THIS EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”), is effective as of June 7, 2021 (the “Effective Date”) by and between Kiromic Biopharma, Inc., a Delaware corporation (the “Company”), and Mr. Ignacio Nunez (the “Executive”). Throughout the remainder of the Agreement, the Company and Executive may be individually referred to as a ‘party” or collectively referred to as “the parties.”
W I T N E S S E T H:
WHEREAS, the Company wishes to employ the Executive, and the Executive desires to accept employment with the Company, upon the terms and conditions of this Agreement.
NOW, THEREFORE, in consideration of the foregoing, of the mutual promises herein, and of other good and valuable consideration, including the employment of the Executive by the Company and the compensation to be received by the Executive from the Company from time to time, and specifically the compensation to be received by the Executive pursuant to Section 4 hereof, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending legally to be bound, hereby agree as follows:
1
Execution
● | Develop and implement manufacturing strategies for the company's cell therapies, ensuring production, tech transfer, build-out, commissioning, facility start-up, process control and life cycle management. |
● | Responsible for long-range strategic planning and implementation for commercial manufacturing, leading to the development and execution of the company's commercial manufacturing teams to drive product-specific technical agendas, from early development through commercial manufacturing. |
● | Responsible for manufacturing site leadership. Make key decisions about site layout, operations, facility, personnel, and future expansion strategy. |
● | Oversee all cGMP manufacturing personnel and activities. |
● | Manage the manufacturing budget with ability to forecast/track facility and manufacturing costs. |
● | Develop a culture of quality and ensure all activities and documentation comply with regulatory requirements. |
● | Implement processes, controls, and methods that align with Global Health Authority regulations. |
● | Execute production and resource schedule against operational plan. |
● | Complete the final review of completed manufacturing documentation per compliance standards and established timelines. |
● | Build a high-performing team by recruiting and developing talent. Provide necessary training and ongoing coaching, discipline and recognition of direct staff, including performing annual performance reviews. |
● | Oversee technology transfer of products and processes into the GMP facility. |
● | Lead and develop a strong winning culture, fostering teamwork and commitment to excellence through transparent communication and staff engagement. |
● | Build a pleasant and inspiring workplace. |
In addition to this list, which includes but does not exhaust all the key responsibilities of the Officer, he is also required to follow what is expressed in Appendix 1 and any changes and additions that may occur.
2
Execution
If to the Company,
Kiromic Biopharma, Inc. 7707 Fannin Street, Suite 140
Houston, TX 77054 Attn: CEO
Email: mchiriva@kiromic.com If to Executive:
NAME
ADDRESS
7
Execution
8
Execution
[The remainder of this page is intentionally left blank.]
9
Execution
IN WITNESS WHEREOF, the parties have executed this Agreement as of the day and year first above written. The Executive must furnish all legal proofs of eligibility to work in the Company.
|
|
| ACCEPTED AND AGREED TO: | ||
| | | KIROMIC BIOPHARMA INC. | ||
| | | | | |
| | | | | |
| | | | | |
| | | | | |
/s/ Ignacio Nunez | | By: | /s/ Maurizio Chiriva-Internati | ||
(Signature) | | | Name: Maurizio Chiriva-Internati | ||
| | | Title: CEO | ||
| | | | | |
| | | | | |
COMO Kiromic | | | | | |
Ignacio Nunez | | | | |
10
Execution
CONFIDENTIAL INFORMATION, INVENTIONS, NON-SOLICITATION AND NON-COMPETITION AGREEMENT
In consideration of my employment by Kiromic Biopharma Inc., and its subsidiaries, parents, affiliates, successors and assigns (together, “Kiromic” or the “Company”) and the compensation now and later paid to me, I hereby enter into this Employee Confidential Information, Inventions, Non Solicitation and Non-Competition Agreement (the “Agreement”) and agree as follows:
indirectly, or to an attorney, and solely for the purpose of reporting or investigating a suspected violation of law; or (2) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.
(b) information regarding research, development, new products, marketing and selling, business plans, budgets and unpublished financial statements, licenses, prices and costs, margins, discounts, credit terms, pricing and billing policies, quoting procedures, methods of obtaining business, forecasts, future plans and potential strategies, financial projections and business strategies, operational plans, financing and capital raising plans, activities and agreements, internal services and operational manuals, methods of conducting Company business, suppliers and supplier information, and purchasing; (c) information regarding customers and potential customers of Company, including customer lists, names,
11
Execution
representatives, their needs or desires with respect to the types of products or services offered by Company, proposals, bids, contracts and their contents and parties, the type and quantity of products and services provided or sought to be provided to customers and potential customers of Company and other non public information relating to customers and potential customers; (d) information regarding any of Company’s business partners and their services, including names; representatives, proposals, bids, contracts and their contents and parties, the type and quantity of products and services received by Company, and other non public information relating to business partners; (e) information regarding personnel, employee lists, compensation, and employee skills; and (f) any other non public information which a competitor of Company could use to the competitive disadvantage of Company. Notwithstanding the foregoing, it is understood that, at all such times, I am free to use information which was known to me prior to employment with Company or which is generally known in the trade or industry through no breach of this Agreement or other act or omission by me. Notwithstanding the foregoing or anything to the contrary in this Agreement or any other agreement between Company and me, nothing in this Agreement shall limit my right to discuss my employment or report possible violations of law or regulation with the Equal Employment Opportunity Commission, United States Department of Labor, the National Labor Relations Board, the Securities and Exchange Commission, or other federal government agency or similar state or local agency or to discuss the terms and conditions of my employment with others to the extent expressly permitted by Section 7 of the National Labor Relations Act or to the extent that such disclosure is protected under the applicable provisions of law or regulation, including but not limited to “whistleblower”
statutes or other similar provisions that protect such disclosure.
12
Execution
Company any unpublished documents or any property belonging to any former employer or any other person to whom I have an obligation of confidentiality unless consented to in writing by that former employer or person.
agree that if I use any Excluded Inventions or any Other Inventions in the scope of my employment, or if I include any Excluded Inventions or Other Inventions in any product or service of Company, or if my rights in any Excluded Inventions or Other Inventions may block or interfere with, or may otherwise be required for, the exercise by Company of any rights assigned to Company under this Agreement, I will immediately so notify Company in writing. Unless Company and I agree otherwise in writing as to particular Excluded Inventions or Other Inventions, I hereby grant to Company, in such circumstances (whether or not I give Company notice as required above), a non exclusive, perpetual, transferable, fully paid and royalty free, irrevocable and worldwide license, with rights to sublicense through multiple levels of sublicensees, to reproduce, make derivative works of, distribute, publicly perform, and publicly display in any form or medium, whether now known or later developed, make, have made, use, sell, import, offer for sale, and exercise any and all present or future rights in, such Excluded Inventions and Other Inventions. To the extent that any third parties have rights in any such Other Inventions, I hereby represent and warrant that such third party or parties have validly and irrevocably granted to me the right to grant the license stated above.
13
Execution
period of my employment by Company. To the extent required by applicable Copyright laws, I agree to assign in the future (when any copyrightable Inventions are first fixed in a tangible medium of expression) my Copyright rights in and to such Inventions. Any assignment of Company Inventions (and all Intellectual Property Rights with respect thereto) hereunder includes an assignment of all Moral Rights. To the extent such Moral Rights cannot be assigned to Kiromic and to the extent the following is allowed by the laws in any country where Moral Rights exist, I hereby unconditionally and irrevocably waive the enforcement of such Moral Rights, and all claims and causes of action of any kind against Company or related to Company’s customers, with respect to such rights. I further acknowledge and agree that neither my successors in interest nor legal heirs retain any Moral Rights in any Company Inventions (and any Intellectual Property Rights with respect thereto).
writing all Inventions authored, conceived, or reduced to practice by me, either alone or jointly with others. In addition, I will promptly disclose to Company all patent applications filed by me or on my behalf within one (1) year after termination of employment. At the time of each such disclosure, I will advise Company in writing of any Inventions that I believe fully qualify for protection under the provisions of any applicable Specific Inventions Law; and I will at that time provide to Company in writing all evidence necessary to substantiate that belief. Company will keep in confidence and will not use for any purpose or disclose to third parties without my consent any Confidential Information disclosed in writing to Company pursuant to this Agreement relating to Inventions that qualify fully for protection under a Specific Inventions Law. I will preserve the confidentiality of any Invention that does not fully qualify for protection under a Specific Inventions Law.
2.7 | Ownership of Work Product. |
14
Execution
worldwide in and to such work product. I understand and agree that I have no right to publish on, submit for publishing, or use for any publication any work product protected by this Section, except as necessary to perform services for Company.
effect as if executed by me. I hereby waive and quitclaim to Company any and all claims, of any nature whatsoever, which I now or may hereafter have for infringement of any Intellectual Property Rights assigned under this Agreement to Kiromic.
15
Execution
reason, including but not limited to voluntary termination by me or involuntary termination by Company, I will not, as an officer, director, employee, consultant, owner, partner, or in any other capacity, either directly or through others, except on behalf of Company:
The parties agree that for purposes of this Agreement, a “Customer or Potential Customer” is any person or entity who or which, at any time during the one (1) year period prior to my contact with such person or entity as described in Sections 5.4 5.6 above if such contact occurs during my employment or, if such contact occurs following the termination of my employment, during the one (1) year period prior to the date my employment with Company ends: (i) contracted for, was billed for, or received from Company any product, service or process with which I worked directly or indirectly during my employment by Company or about which I acquired Confidential Information; or (ii) was in contact with me or in contact with any other employee, owner, or agent of Company, of which contact I was or should have been aware, concerning the sale or purchase of, or contract for, any product, service or process with which I worked directly or indirectly during my employment with Company or about which I acquired Confidential Information; or (iii) was solicited by Company in an effort in which I was involved or of which I was aware.
16
Execution
perform, or provide, or attempt to perform or provide Conflicting Services anywhere in the Restricted Territory (as defined below), nor will I assist another person to solicit, perform or provide or attempt to perform or provide Conflicting Services anywhere in the Restricted Territory.
The parties agree that for purposes of this Agreement, “Conflicting Services” means any product, service, or process or the research and development thereof, of any person or organization other than Company that directly competes with a product, service, or process, including the research and development thereof, of Company with which I worked directly or indirectly during my employment by Company or about which I acquired Confidential Information during my employment by Company.
The parties agree that for purposes of this Agreement, “Restricted Territory” means the one hundred (100) mile radius of any of the following locations: (i) any Company business location at which I have worked on a regular or occasional basis during the preceding year; (ii) my home if I work from home on a regular or occasional basis; (iii) any potential business location of Company under active consideration by Company to which I have traveled in connection with the consideration of that location; (iv) the primary business location of a Customer or Potential Customer; or (v) any business location of a Customer or Potential Customer where representatives of the Customer or Potential Customer with whom I have been in contact in the preceding year are based.
are reasonable, proper, and necessitated by Company’s legitimate business interests. I represent and agree that I am entering into this Agreement freely and with knowledge of its contents with the intent to be bound by the Agreement and the restrictions contained in it.
17
Execution
does not and will not breach any agreement to keep in confidence information acquired by me in confidence or in trust prior to my employment by Company. I have not entered into, and I agree I will not enter into, any agreement either written or oral in conflict with this Agreement.
10. | LEGAL AND EQUITABLE REMEDIES. |
18
Execution
13. | GENERAL PROVISIONS. |
for any reason, be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability will not affect the other provisions of this Agreement, and this Agreement will be construed as if such invalid, illegal or unenforceable provision had never been contained in this Agreement. If moreover, any one or more of the provisions contained in this Agreement will for any reason be held to be excessively broad as to duration, geographical scope, activity or subject, it will be construed by limiting and reducing it, so as to be enforceable to the extent compatible with the applicable law as it will then appear.
19
Execution
20
Execution
This Agreement will be effective as of June 7, 2021.
I HAVE READ THIS AGREEMENT CAREFULLY AND UNDERSTAND ITS TERMS. I HAVE COMPLETELY FILLED OUT EXHIBIT F TO THIS AGREEMENT.
|
|
| ACCEPTED AND AGREED TO: | ||
| | | KIROMIC BIOPHARMA INC. | ||
| | | | | |
| | | | | |
| | | | | |
| | | | | |
/s/ Ignacio Nunez | | By: | /s/ Maurizio Chiriva-Internati | ||
(Signature) | | | Name: Maurizio Chiriva-Internati | ||
| | | Title: CEO | ||
| | | | | |
| | | | | |
COMO Kiromic | | | | | |
Ignacio Nunez | | | | |
21
844.KEY.CURE | www.kiromic.com
Kiromic Announces
Expansion of In-House Cell therapy cGMP Manufacturing Facility and
the Appointment of Industry Veteran Ignacio Núñez as
Chief Operating and Manufacturing Officer
Houston, Texas, June 7th, 2021 /Business Wire/ -- Kiromic BioPharma, Inc. (Nasdaq: KRBP)
— | Expansion of in-house cGMP manufacturing facility to provide support to the Company's clinical trials. Therapeutic doses expected to be ready for first in-human dosing in |
— | Mr. Ignacio Núñez, a 20-year industry veteran in global operations and manufacturing, is joining the Kiromic team to take the company to the next level and to scale up cGMP manufacturing capabilities internally. |
Kiromic is an immuno-oncology company using Artificial Intelligence (AI) to identify critical markers in solid tumors to develop Allogeneic CAR-T cell therapy.
Kiromic’s CAR-T technology addresses critical efficacy and safety issues by developing switches to control T-cell activity reducing cell exhaustion and cytokine release syndrome among others.
-------------
Expansion of in-house cGMP manufacturing facility
In support of the upcoming INDs, Kiromic is expanding its HQ in Houston, TX. To their current cGMP, R&D labs, vivarium and offices, Kiromic is adding an adjacent space where more cGMP clean rooms, QC, QA and regulatory, offices and ultra-cold storage will have place.
This new expansion will add up to a total of approximately 30,000 square feet and will enable supporting Kiromic significant growth as the company approaches the clinical phase.
Appointment of Chief Operating and Manufacturing Officer
Mr. Ignacio Núñez MSCHE, MBB has been appointed as Chief Operating Officer and Manufacturing Officer.
SMRH:4810-4346-9805.1 | -1- | |
| | |
Mr. Núñez will play a key role in expanding the scale up of Kiromic’s operations, including manufacturing, taking the company from pre-IND status to the clinical phase and eventually to commercial phase.
Mr. Núñez has over 20 years of global experience in corporate functions including manufacturing, research, operational excellence and strategy. He has held senior leadership positions in companies including General Electric, Johnson & Johnson and Novartis. Most recently, he was the Executive Director of Manufacturing at the Gene Therapy Program of the University of Pennsylvania.
Before that, he was the Head of Manufacturing Strategy and Operations Excellence at Novartis, where he was charged with transforming manufacturing operations in support of the ramp up of Kymriah, the first FDA-approved CAR-T cell therapy, which was developed at the University of Pennsylvania.
Mr. Núñez holds an MSC in Chemical Engineering from the University of Granada.
CEO of Kiromic, Maurizio Chiriva-Internati, DBSc, PhDs
“Kiromic believes it has the key to resolve the current challenges in cell therapy and I believe we will become the reference and lead the industry going forward.”
Cell Therapy Manufacturing: Autologous (patient) vs. Allogeneic (healthy donor)
The table below outlines the current cell therapy manufacturing challenges which Kiromic allogeneic cell manufacturing expects to resolve and which Mr. Núñez will advance.
Safety | |||
Efficacy | |||
SMRH:4810-4346-9805.1 | -2- | |
| | |
Manufacturing | |||
Application | |||
(*) based upon Kiromic's pre-clinical projections, AACR posters (**) as filed in IND to the FDA (May 2021).
COMO of Kiromic, Mr. Ignacio Núñez stated:
" I am impressed by Kiromic’s end-to-end approach to cell therapy as I believe they address almost every known issue in current cell therapies.
Expanded Kiromic in-house manufacturing capabilities are capital efficient and are optimized to deliver the capacity projections, making manufacturing a competitive advantage and not a challenge for the company.
I believe that this technology is meant to change the cell and gene therapy landscape, reshaping the future approach to cancer treatment.
I am humbled to join the team at this critical juncture."
CMO of Kiromic, Scott Dahlbeck, MD, PharmD stated:
“Kiromic is pleased to obtain the clinical manufacturing expertise of Mr. Núñez, whose expertise and biopharmaceutical background I believe will serve to capitalize on the cellular therapy production capabilities of Kiromic, leading to a new era in immuno-oncology treatments for solid tumors."
CSIO of Kiromic, Mr. Gianluca Rotino stated:
"I believe all of our cell therapy manufacturing is novel and resolves key industry challenges.
It is my opinion, that our manufacturing technology will be very much sought after by pharma companies and cell therapy industry players.
Our cell therapy IPs portfolio is very strong.
This manufacturing expansion and bringing Mr. Nunez to Kiromic are strategically important milestones that makes us ready to face the challenges of the clinical trials and puts us on the path of commercial viability of our novel therapy."
SMRH:4810-4346-9805.1 | -3- | |
| | |
CFO of Kiromic, Mr. Tony Tontat stated:
"Capital efficiency is what we strove to deliver with our investments as we were building out our cGMP facility.
We are happy to receive this additional validation of capital efficiency from an industry veteran like Mr. Núñez."
How Our KB-PD1 Live Cell Therapy CAR-T Improves CAR-T Market:
SMRH:4810-4346-9805.1 | -4- | |
| | |
About Kiromic Scientific Posters Presented at AACR 2021
Session | Focus | Poster | Link to Poster at AACR
|
BSB01.05 | New Software for Data Analysis | 247 | Identification of an ovarian cancer selective splice variant of mesothelin utilizing the Kiromic proprietary search engine CancerDiff
CancerDiff: Our deep data-mining engine which harmonizes billions of data points across: -- disease types and states -- data types, -- data structures, and -- data platforms.
Diamond AI: Our system which combs through billions of transcription data points across public and private RNA databases to present the best immunogenic peptide candidates for CAR-T.
|
PO.IM02.01 | Adoptive Cell Therapy | 1534 | Mesothelin isoform 2 is a novel target for allogeneic CARγδT cell therapy in solid tumors
CancerSplice: Our 3D, isoform prediction engine which examines billions of data points to select the best targets.
|
BSB01.04 | New Algorithms
| 243 | Identification of novel epitopes of NY-ESO-1 for solid malignancies by Kiromic proprietary search engine Diamond
NY-ESO-1: How we got to NY-ESO-1 using our AI target selection engine. NY-EOS-1 is a very well-known target and served as an excellent validation of our engine's accuracy. |
SMRH:4810-4346-9805.1
-5-
| |||
PO.ET08.01 | Gene and Vector-Based Therapy | 1154 | Site-specific gene editing with ABBIE for T-cell therapy
ABBIE: We showed that our non-viral gene edit technology could have the same target specificity of Cas9 without the DNA destruction common to HIV integrase.
|
PO.IM02.01 | Adoptive Cell Therapy | LB148 | Gamma delta T cells engineered with a chimeric PD-1 receptor effectively control PD-L1 positive tumors in vitro and in vivo with minimal toxicities.
chPD1: We demonstrated that our chPD1 receptor was effective on solid tumors in both in vitro and in vivo models with minimal toxicities.
|
PO.IM02.01 | Adoptive Cell Therapy | 1535 | Allogeneic CAR iNKT as a cell therapy platform targeting tumor antigen Isomesothelin
iNKT: We investigated NK as a potential adoptive cell therapy platform for CAR-T.
|
About AACR (American Association of Cancer Research)
www.aacr.org
SMRH:4810-4346-9805.1 | -6- | |
| | |
About Kiromic
Kiromic BioPharma, Inc. (Nasdaq: KRBP) is a target discovery and gene-editing company utilizing a state-of-the-art artificial intelligence (AI) platform focused on unleashing the power of the patient’s own immune system to fight cancer.
Kiromic’s pipeline development is leveraged through the Company’s proprietary target discovery Artificial Intelligence engine called "DIAMOND." Kiromic's DIAMOND is big data science meeting target identification, dramatically compressing the man-years and the millions of drug development dollars needed to develop a live drug.
The Company maintains its HQ offices in the world’s largest medical center in Houston, Texas adjacent to MD Anderson Cancer Center and the Baylor College of Medicine Where Kiromic has ongoing collaboration with these Institutions.
For more information, please visit the company’s website at www.kiromic.com.
Forward-Looking Statements
This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” "will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on our company’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the Company’s annual report on Form 10-K for the most recently completed fiscal year and subsequent reports filed after the date of the annual report with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and our company undertakes no duty to update such information except as required under applicable law.
Contact:
Investor Relations
inv.rel@kiromic.com
Tony Tontat - CFO
(844) 539 - 2873
Source: Kiromic Biopharma, Inc. (www.kiromic.com)
SMRH:4810-4346-9805.1 | -7- | |
| | |